Latest Summit Therapeutics News & Updates

See the latest news and media coverage for Summit Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Summit Therapeutics

Biopharmaceutical oncology company developing cancer therapies

smmttx.com

Headquarters: Miami, United States
Founded year: 2003
Company type: Public company
Number of employees: 400–500
Industry: Pharmaceuticals

Last updated Today

Latest news about Summit Therapeutics

In short: Summit Therapeutics announced positive Phase III data for ivonescimab and progressed toward a 2026 FDA submission.

Company announcements

Yesterday Summit Therapeutics

Summit announces Phase III HARMONi-GI1 data for ivonescimab in biliary tract cancer

The trial showed superior overall survival versus durvalumab plus chemotherapy. Results will present at ESMO 2026 presidential symposium.

September 15 Summit Therapeutics

Summit Therapeutics reports updated HARMONi survival data

Updated Phase III results show consistent overall survival benefits for ivonescimab plus chemotherapy across Western and Asian NSCLC patient populations with no new safety signals.

September 13 Summit Therapeutics

Summit Therapeutics partner Akeso reports positive HARMONi-2 overall survival data

The Phase III trial shows ivonescimab reduces death risk by 27% versus pembrolizumab in PD-L1 positive NSCLC. These results support the ongoing global HARMONi-7 study.

July 23 Summit Therapeutics

Summit Therapeutics held its Q2 2026 earnings call

The presentation was published on July 23, 2026, offering financial insights and updates on the company's clinical pipeline and commercial progress.

Media coverage

Yesterday Marketscreener

Akeso, Inc. and Summit Therapeutics Inc. present data from the phase III HARMONi-GI1 study on ivonescimab plus ... at ESMO 2026

Summit Therapeutics Inc. announced that data from the phase III HARMONi-GI1 study, conducted in China and sponsored by Akeso, Inc., focused on the new ...

September 20 BioPharma Dive

Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.

September 16 Traders Union

Summit Therapeutics shares fall more than 5%: update on HARMONi study triggered selling pressure...

Today, Summit Therapeutics is down 5.13% to $16.94 following updated Phase III data; further volatility is expected in upcoming sessions.

September 15 Marketscreener

Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients

Summit Therapeutics Inc. announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific...

Never miss news about Summit Therapeutics

Track Summit Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Summit Therapeutics competitors & trending companies

Browse news for competitors to Summit Therapeutics and other trending companies.